Heminevrin (Clomethiazole)

Heminevrin is indicated for specific clinical situations where rapid control of central nervous system hyperactivity is required.

• Management of acute alcohol withdrawal syndrome to reduce the risk of seizures and delirium tremens.
• Short‑term sedation for patients undergoing invasive procedures or requiring intensive care monitoring.
• Adjunctive treatment in severe agitation when other sedatives are contraindicated.
• Temporary relief of severe insomnia associated with alcohol dependence.
• Use in hospital settings for rapid tranquilization under physician supervision.

The pharmacological activity of clomethiazole can produce a range of adverse effects, which are generally classified by frequency and severity.

Common

• Drowsiness or somnolence, often noticeable within the first few hours after dosing.
• Dizziness or a light‑headed sensation, particularly when standing up quickly.
• Headache that may vary from mild to moderate intensity.
• Nausea or mild gastrointestinal upset, sometimes accompanied by abdominal discomfort.
• Dry mouth or altered taste perception.

Serious

• Respiratory depression, especially when combined with other depressants, which can be life‑threatening.
• Severe hypotension or cardiovascular instability requiring medical intervention.
• Hepatic dysfunction or elevated liver enzymes indicating possible liver injury.
• Allergic reactions such as rash, itching, swelling, or angioedema.
• Seizures or paradoxical excitation despite the drug’s sedative intent.

Because Heminevrin influences central nervous system activity, several precautions should be observed before and during therapy.

• Assess patient history for respiratory disorders, such as asthma or chronic obstructive pulmonary disease.
• Evaluate liver function, as clomethiazole is metabolized hepatically and may accumulate in hepatic impairment.
• Use caution in elderly patients due to increased sensitivity to sedative effects.
• Avoid abrupt discontinuation to prevent withdrawal symptoms or rebound agitation.
• Monitor for signs of excessive sedation, especially when combined with alcohol or other CNS depressants.
• Conduct regular blood pressure and heart rate checks during initial dosing.
• Review pregnancy and breastfeeding status, although safety data are limited.

Clomethiazole can interact with other substances that affect the central nervous system or hepatic metabolism, requiring careful management.

Avoid

• Alcohol, because combined use can cause profound respiratory depression and profound sedation.
• Other CNS depressants such as benzodiazepines, opioids, or barbiturates, which may lead to additive sedative effects and risk of overdose.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) that could increase clomethiazole plasma concentrations.
• Monoamine oxidase inhibitors (MAOIs) due to potential unpredictable central effects.

Use with caution

• CNS stimulants (e.g., caffeine, certain antidepressants) that may counteract sedative action.
• Antihistamines or antihypertensive agents, which could enhance drowsiness or lower blood pressure.
• Herbal supplements like St. John’s wort that induce hepatic enzymes and may reduce efficacy.
• Anticonvulsants, as clomethiazole may alter seizure threshold.